Korsana Biosciences, Inc. Common Stock
KRSA
95 hedge funds and large institutions have $223M invested in Korsana Biosciences, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 95 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71.06% more ownership
Funds ownership: 0% → 71.06% (+71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.53M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.26M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$3.16M |
| 4 |
MP
MFN Partners
Boston,
Massachusetts
|
+$3.01M |
| 5 |
BlackRock
New York
|
+$2.99M |
Top Sellers
KRSA Hedge Fund Activity: Q2 2019 in Review
95 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q2 2019, worth a combined $223M.
Buyers outnumbered sellers: 95 funds opened new KRSA positions and 0 closed out — a net gain of 95 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $5.53M.
- 95 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $223M of Korsana Biosciences, Inc. Common Stock stock for Q2 2019.
- 95 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +95 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q2 2019 was Fidelity Investments, an estimated $5.53M added.
Based on aggregated 13F filings for Q2 2019.